Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial
Author(s)
Type
Journal Article
Date Issued
2015-01-01
ISSN
2044-6055
Publisher
BMJ PUBLISHING GROUP
Journal / Book Title
BMJ OPEN
Volume
5
Issue
9
Copyright Statement
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Sponsor
National Institute for Health Research
National Institute for Health Research
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363484000052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
RP-PG-0608-10079
SIVS1012 CLARITY
Subjects
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
ENDOTHELIAL GROWTH-FACTOR
PSYCHOMETRIC DEVELOPMENT
FACTOR VEGF
QUESTIONNAIRE
NEOVASCULARIZATION
INHIBITION
PRIMATE
Angiogenesis Inhibitors
Diabetic Retinopathy
Female
Humans
Intravitreal Injections
Male
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Publication Status
Published
Article Number
ARTN e008405